Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S282-S294

  Brannan, Jennifer M ^a   Froude, Jeffery W ^a   Prugar, Laura I ^a   Bakken, Russell R ^a   Zak, Samantha E ^a   Daye, Sharon P ^a   Wilhelmsen, Catherine E ^a   Dye, John M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

coagulopathy; Ebola virus; Ebola virus disease; mouse model; pathogenesis; Sudan virus

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; EBOLA VACCINE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13C6; MONOCLONAL ANTIBODY 16F6; MONOCLONAL ANTIBODY 19F10; UNCLASSIFIED DRUG; GLYCOPROTEIN; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BUNDIBUGYO EBOLAVIRUS; CONTROLLED STUDY; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FILOVIRIDAE; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESTON VIRUS; SUDAN EBOLAVIRUS; TAI FOREST VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIRUS REPLICATION; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CELL LINE; CHLOROCEBUS AETHIOPS; DEFICIENCY; DISEASE MODEL; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY; PROCEDURES; REPLICON; VACCINATION; VERO CELL LINE; VIROLOGY; VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; EBOLA VACCINES; EBOLAVIRUS; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; MICE; MICE, INBRED C57BL; RECEPTOR, INTERFERON ALPHA-BETA; REPLICON; VACCINATION; VERO CELLS; VIRAL PROTEINS; VIRULENCE;

EID: 84943249571     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv215     Document Type: Article

References (42)

1. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Fields BN, ed. Fields virology. Philadelphia: Lippincott,Williams and Wilkins, 2007:1409-48.
2. CDC, Prevention CfDCa. 2014 Ebola outbreak in West Africa-case counts 2014. http://www.cdc.gov/vhf/ebola/outbreaks/2014-westafrica/ case-counts.html. Accessed 5 January 2014.
3. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849-62.
4. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56:271-93.
5. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 1978; 56:247-70.
6. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4:e1000212.
7. Kuhn JH, Becker S, Ebihara H, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010; 155:2083-103.
8. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995; 345:1271-4.
9. Miranda ME, Ksiazek TG, Retuya TJ, et al. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis 1999; 179(suppl 1):S115-9.
10. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009; 2:12-7.
11. Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. Front Microbiol 2013; 4:267.
12. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
13. Bradfute SB, Warfield KL, Bray M. Mouse models for filovirus infections. Viruses 2012; 4:1477-508.
14. Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001; 125:243-53.
15. Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006; 2:e73.
16. Zumbrun EE, Abdeltawab NF, Bloomfield HA, et al. Development of a murine model for aerosolized ebolavirus infection using a panel of recombinant inbred mice. Viruses 2012; 4:3468-93.
17. Rasmussen AL, Okumura A, Ferris MT, et al. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 2014; 346:987-91.
18. Bray M. The role of the type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 2001; 82:1365-73.
19. Lever MS, Piercy TJ, Steward JA, et al. Lethality and pathogenesis of airborne infection with filoviruses in A129 alpha/beta-/- interferon receptor-deficient mice. J Med Microbiol 2012; 61:8-15.
20. National Research Council. Guide for the care and use of laboratory animals. 8th ed. Washington, DC: National Academies Press, 2011.
21. Moe JB, Lambert RD, Lupton HW. Plaque assay for Ebola virus. J Clin Microbiol 1981; 13:791-3.
22. Olinger GG, Bailey MA, Dye JM, et al. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 2005; 79:14189-96.
23. Herbert AS, Kuehne AI, Barth JF, et al. Venezuelan equine encephalitis replicon particle vaccine protects nonhuman primates from ebolavirus intramuscular and aerosol challenge. J Virol 2013; 87:4952-64.
24. Fenimore PW, Muhammad MA, Fischer WM, et al. Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage. PloS One 2012; 7:e44769.
25. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179(suppl 1): S203-17.
26. Ebihara H, Zivcec M, Gardner D, et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis 2013; 207:306-18.
27. Lefebvre A, Fiet C, Belpois-Duchamp C, Tiv M, Astruc K, Aho Glele LS. Case fatality rates of Ebola virus diseases: A meta-analysis of World Health Organization data. Med Mal Infect 2014; 44:412-6.
28. Kuhn JH, Lofts LL, Kugelman JR, et al. Reidentification of Ebola Virus E718 and ME as Ebola Virus/H.sapiens-tc/COD/1976/Yambuku-Ecran. Genome Announc 2014; 2:1-2.
29. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196(suppl 2): S364-71.
30. Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007; 196(suppl 2):S390-9.
31. Bradfute SB, Braun DR, Shamblin JD, et al. Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis 2007; 196(suppl 2): S296-304.
32. Bradfute SB, Swanson PE, Smith MA, et al. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J Immunol 2010; 184:327-35.
33. Bradfute SB,Warfield KL, Bavari S. Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol 2008; 180:4058-66.
34. Balachandran S, Roberts PC, Kipperman T, et al. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/ Caspase-8 death signaling pathway. J Virol 2000; 74:1513-23.
35. O'Brien LM, Stokes MG, Lonsdale SG, et al. Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse. Virology 2014; 452-453:324-33.
36. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446-54.
37. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014; 104:153-5.
38. Chen G, Koellhoffer JF, Zak SE, et al. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. ACS Chem Biol 2014; 9:2263-73.
39. Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibodymediated protection from Ebola virus. Science 2000; 287:1664-6.
40. Gupta M, Goldsmith CS, Metcalfe MG, Spiropoulou CF, Rollin PE. Reduced virus replication, proinflammatory cytokine production, and delayed macrophage cell death in human PBMCs infected with the newly discovered Bundibugyo ebolavirus relative to Zaire ebolavirus. Virology 2010; 402:203-8.
41. Basler CF, Amarasinghe GK. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 2009; 29:511-20.
42. Kash JC, Muhlberger E, Carter V, et al. Global suppression of the host antiviral response by Ebola-and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 2006; 80:3009-20.